Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis

Mark Gudesblatt; Karl Wissemann; Myassar Zarif; Barbara Bumstead; Lori Fafard; Jeffrey Wilken; Karen Blitz; Marijean Buhse; Sourav Santra; Christophe Hotermans; Lily Lee

doi:10.1007/s40263-018-0574-9

Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis

CNS Drugs. 2018 Dec;32(12):1183. doi: 10.1007/s40263-018-0574-9.

Authors

Affiliations

¹ South Shore Neurologic Associates, Patchogue, NY, USA.
² Washington Neuropsychology Research Group LLC, Fairfax, VA, USA.
³ Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.
⁴ Biogen, 225 Binney Street, Cambridge, MA, 02142, USA. lily.lee@biogen.com.

Abstract

An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 24 August 2018. An error was subsequently identified in the article, and the following correction should be noted.

Publication types

Published Erratum